BCHT(SH:688276) Shang Hai Zheng Quan Bao·2026-01-16 21:01Group 1 - The company expects a net profit loss for the year 2025, estimated between -220 million to -280 million yuan, representing a decrease of 194.79% to 220.64% compared to the previous year [3] - The net profit after deducting non-recurring gains and losses is projected to be between -240 million to -300 million yuan, a decrease of 204.43% to 230.54% year-on-year [3] - The previous year's net profit was 232.09 million yuan, with a total profit of 255.77 million yuan [5] Group 2 - The decline in revenue is attributed to intensified industry competition, insufficient public vaccination willingness, and a decrease in newborn birth rates [7] - Sales revenue from the company's main product, the herpes zoster vaccine, has significantly declined due to various factors affecting consumer awareness and willingness to vaccinate [7] - The company is implementing multiple marketing initiatives to activate market potential, including price adjustments and expanding product promotion channels [7][8] Group 3 - The company has recognized asset impairment losses to reflect its financial status accurately, based on the prudence principle [9] - Investment losses were confirmed due to capital increases in associated companies, accounted for using the equity method [9]